Cetirizine hydrochloride is a Small Molecule owned by NicOx, and is involved in 10 clinical trials, of which 9 were completed, and 1 is ongoing.

Cetirizine hydrochloride competes with histamine for binding at H1-receptor sites on the effector cell surface, which blocks the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. By blocking H1-receptor, the drug candidate significantly reduces the effects of allergens.

The revenue for Cetirizine hydrochloride is expected to reach a total of $199m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cetirizine hydrochloride NPV Report.

Cetirizine hydrochloride is currently owned by NicOx. Ocumension Therapeutics is the other company associated in development or marketing of Cetirizine hydrochloride.

Cetirizine hydrochloride Overview

Cetirizine hydrochloride (AC-170, Zerviate) is a diphenylmethane derivative, acts as an antihistamine agent. It is formulated as solution for ophthalmic route of administration. Zerviate is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Cetirizine hydrochloride (OT-1001) is under development for the treatment of allergic conjunctivitis in China.

Ocumension Therapeutics Overview

Ocumension Therapeutics (Ocumension) develops and provides prescription medicines that meet the evolving needs of patients, healthcare professionals, and caregivers. Ocumension is headquartered in Suzhou, Suzhou, China.

The company reported revenues of (Renminbi) CNY56.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CNY13.1 million in FY2020. The operating loss of the company was CNY246.1 million in FY2021, compared to an operating loss of CNY2,264.8 million in FY2020. The net loss of the company was CNY260 million in FY2021, compared to a net loss of CNY2,264.9 million in FY2020.

Quick View – Cetirizine hydrochloride

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Cetirizine hydrochloride
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.